Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Think Research Corporation V.THNK

Think Research Corporation is a Canada-based company that offers digital health software solutions. It is a provider of cloud-based data, knowledge, and software solutions primarily delivered as software-as-a-service (SaaS) to healthcare delivery systems and the practitioners that they support. Its operations are organized into three lines of business: Software and Data Solutions, Clinical Research, and Clinical Services. Its SaaS solutions help patients find, navigate, and connect to health services across large governments and payer clients, while also ensuring safety for prescribed medications at pharmacies. Through its wholly owned subsidiary, BioPharma Services Inc., the Company provides research data and analysis derived from Phase I clinical trials, bioequivalence studies and bioanalytical services. Its clinics act as a test bed for its software and technology, transforming them with digital solutions that optimize clinical outcomes, streamline workflows, and optimize billing.


TSXV:THNK - Post by User

Comment by RomanNumeralon Feb 04, 2021 5:01pm
235 Views
Post# 32479273

RE:RE:RE:I hate it when management give themselves option at $4.37

RE:RE:RE:I hate it when management give themselves option at $4.37I'm surprised the issuance of ITM options that vest over three years is offensive, yet you aren't offended by the exec's salaries given their performance:

"Mr. Aggarwal earns a base salary of $375,000, is entitled to four weeks’ vacation, and is eligible for a discretionary cash bonus of up to 100% of his annual base salary based upon achievement of personal goals and company performance."

"Mr. Mukhi earns a base salary of $250,000, is entitled to four weeks’ vacation, and is eligible for a discretionary cash bonus of up to 100% of his annual base salary based upon achievement of personal goals and company performance."

"Ms. Carroll earns a base salary of $250,000, is entitled to four weeks’ vacation, and is eligible for a discretionary cash bonus of up to 100% of her annual base salary based upon achievement of personal goals and company performance."

"Mr. Singh earns a base salary of $250,000, is entitled to four weeks’ vacation, and is eligible for a discretionary cash bonus of up to 100% of his annual base salary based upon achievement of personal goals and company performance."

- pg 72-74 of 501 of the Filing Statement dated Nov 30, 2020 (see Sedar)

Those options might be profitable one day, but the salaries above are a real cash cost! The management team steered the ship to ONLY a loss of $10.6M in the last year! 

Why do you think they went public? People got tired writing blank checks for this exec team to burn through.

<< Previous
Bullboard Posts
Next >>